| Literature DB >> 24328058 |
Weiran Cheng1, Inga E Haedicke, Joris Nofiele, Francisco Martinez, Kiran Beera, Timothy J Scholl, Hai-Ling Margaret Cheng, Xiao-An Zhang.
Abstract
Mn(III) porphyrin (MnP) holds the promise of addressing the emerging challenges associated with Gd-based clinical MRI contrast agents (CAs), namely, Gd-related adverse effect and decreasing sensitivity at high clinical magnetic fields. Two complementary strategies for developing new MnPs as Gd-free CAs with optimized biocompatibility were established to improve relaxivity or clearance rate. MnPs with distinct and tunable pharmacokinetic properties can consequently be constructed for different in vivo applications at clinical field of 3 T.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24328058 DOI： 10.1021/jm401124b
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446